Skip to main content

Payers' Guide

Payers' Guide, FDA Approvals

Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Payers' Guide, FDA Approvals

Eylea (Aflibercept) Receives FDA Approval of New Dose for Age-Related Macular Degeneration

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

FDA Approvals of Novel Brand-Name Prescription Drugs in 2018

Payers' Guide, FDA Approvals

Ilumya (Tildrakizumab-asmn), Interleukin-23 Antagonist, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination FDA Approved for the Treatment of Waldenström’s Macroglobulinemia

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma

Payers' Guide, FDA Approvals

Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin Approved for Relapsed or Refractory Hairy-Cell Leukemia

Lisa A. Raedler, PhD, RPh

FDA Approvals, Oncology Overview, Payers' Guide, Oncology

New Indications Approved by the FDA in 2018 for Oncology Drugs

Dalia Buffery, MA, ABD

Payers' Guide, FDA Approvals

Nuzyra (Omadacycline) Approved for the Treatment of Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure Infections

Page 1 of 19
Results 1 - 10 of 185